SAB Biotherapeutics Inc (SABS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SAB Biotherapeutics Inc (SABS) has a cash flow conversion efficiency ratio of -0.079x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.05 Million) by net assets ($165.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SAB Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how SAB Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SAB Biotherapeutics Inc (SABS) financial obligations for a breakdown of total debt and financial obligations.
SAB Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SAB Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Socovesa
SN:SOCOVESA
|
-0.126x |
|
Teladan Setia Group Bhd
KLSE:0230
|
0.033x |
|
Greenland Resources Inc
NEO:MOLY
|
-0.139x |
|
Kao Hsiung Chang Iron & Steel Corp
TW:2008
|
0.022x |
|
centrotherm international AG
F:CTNK
|
0.077x |
|
Vieworks Co. Ltd
KQ:100120
|
0.076x |
|
Humacyte Inc
NASDAQ:HUMA
|
5.031x |
|
PHX Minerals Inc
NYSE:PHX
|
0.034x |
Annual Cash Flow Conversion Efficiency for SAB Biotherapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of SAB Biotherapeutics Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see SAB Biotherapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $25.97 Million | $-34.29 Million | -1.320x | -201.21% |
| 2023-12-31 | $57.30 Million | $-25.12 Million | -0.438x | +41.96% |
| 2022-12-31 | $31.06 Million | $-23.46 Million | -0.755x | -1565.54% |
| 2021-12-31 | $38.55 Million | $1.99 Million | 0.052x | -79.90% |
| 2020-12-31 | $39.01 Million | $10.00 Million | 0.256x | -93.58% |
| 2019-12-31 | $-2.31 Million | $-9.21 Million | 3.997x | -- |
About SAB Biotherapeutics Inc
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune… Read more